

**Important notes:**

Do **NOT** write outside the grey boxes. Any text or images outside the boxes **will** be deleted.

Do **NOT** alter the structure of this form. Simply enter your information into the boxes. The form will be automatically processed – if you alter its structure your submission will not be processed correctly.

Do not include keywords – you can add them when you submit the abstract online.

**Title:**

**Microacoustic biosensor for label-free assessment of von Willebrand factor function in primary haemostasis**

**Authors & affiliations:**

Please do not include Personal Data (email address, postal address, etc.) in this field. Include only author names & affiliations

A. Oseev<sup>\*1</sup>, T. Lecompte<sup>2</sup>, F. Remy-Martin<sup>1</sup>, C. Élie-Caille<sup>1</sup>, G. Mourey<sup>3,4,5</sup>, E. de Maistre<sup>6</sup>, A. Rouleau<sup>1</sup>, F. Chollet<sup>1</sup>, J.-F. Manceau<sup>1</sup>, W. Boireau<sup>1</sup> and T. Leblois<sup>1</sup>

<sup>1</sup>FEMTO-ST institute, CNRS UMR-6174, Université de Bourgogne Franche-Comté, Besançon, France;

<sup>2</sup>Geneva University (faculty of medicine, Geneva Platelet Group), and University Hospital HUG

(Haemostasis Unit), Geneva, Switzerland; <sup>3</sup>Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France;

<sup>4</sup>University Hospital of Besançon, Clinical Haemostasis Unit, Besançon, France; <sup>5</sup>EFS BFC, Haemostasis Division, Laboratoire de Biologie Médicale et de Greffe, Besançon, France; <sup>6</sup>Centre Hospitalier Universitaire de Dijon-Bourgogne, Dijon, France

**Abstract:** (Your abstract must use **Normal style** and must fit in this box. Your abstract should be no longer than 300 words. The box will 'expand' over 2 pages as you add text/diagrams into it.)

**Preparation of Your Abstract**

1. The title should be as brief as possible but long enough to indicate clearly the nature of the study. Capitalise the first letter of the first word **ONLY** (place names excluded). No full stop at the end.

2. Abstracts should state briefly and clearly the purpose, methods, results and conclusions of the work.

Introduction: Clearly state the purpose of the abstract

Methods: Describe your selection of observations or experimental subjects clearly

Results: Present your results in a logical sequence in text, tables and illustrations

Discussion: Emphasize new and important aspects of the study and conclusions that are drawn from them

**Important notes:**

Do **NOT** write outside the grey boxes. Any text or images outside the boxes **will** be deleted.

Do **NOT** alter the structure of this form. Simply enter your information into the boxes. The form will be automatically processed – if you alter its structure your submission will not be processed correctly.

Do not include keywords – you can add them when you submit the abstract online.

Under shear rate conditions prevailing in the microcirculation, vWF- platelet GpIb interaction is a prerequisite of haemostatic plug formation (primary haemostasis: platelet adhesion followed by aggregation). In order to better investigate von Willebrand disease (vWD) and platelet disorders associated with bleeding, we propose to perform real-time evaluation under several shear rates at which the contribution of vWF in platelet plug formation differs.

We designed a label-free assessment with a microacoustic biosensor based on quartz crystal microbalance (QCM), Figure 1. The biosensor frequency shift was prior compared with atomic force microscopy (AFM) images of the biointerface after perfusion and found to be in agreement with both coverage and average height of platelet deposits, Figure 2. The test results for 5 minutes perfusion of anticoagulated normal whole blood are shown in Figures 3(a)-4(a). Defective adhesion was induced by inhibition of GpIb platelet receptor with a monoclonal antibody at 10ug/mL. Perfusion results are shown in Figures 3(b)-4(b). Inhibition of GpIb affected initial platelet plug formation in all cases but less at 200 1/s when the contribution of vWF is expected to be the lowest.

The approach we developed is intended to improve evaluation of vWD in a label-free manner by integrative shear dependent phenotyping that is not realised by currently existing devices.




Figure 1. Parallel plate flow perfusion chamber with assembled biosensor (a); AFM image of collagen type I biointerface (b); experimental setup (c).




Figure 2. Frequency shift versus AFM measured surface platelet coverage (a) and average height (b) for two blood samples.

**Important notes:**

Do **NOT** write outside the grey boxes. Any text or images outside the boxes **will** be deleted.

Do **NOT** alter the structure of this form. Simply enter your information into the boxes. The form will be automatically processed – if you alter its structure your submission will not be processed correctly.

Do not include keywords – you can add them when you submit the abstract online.




Figure 3. Test results of perfusion of whole blood without (a) and with (b) GpIb inhibition.




Figure 4. Representative AFM images of platelet deposits after perfusion (5 minutes) of normal (a) and GpIb inhibited (b) whole blood.